US urges all WTO members to support intellectual property waiver for COVID-19 vaccines

More than 100 countries backing the waiver say it will help save lives


Reuters October 22, 2021
Vials labelled "AstraZeneca, Pfizer - Biontech, Johnson&Johnson, Sputnik V coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. PHOTO: REUTERS

WASHINGTON:

The White House on Thursday called on all World Trade Organization members to support an intellectual property waiver for COVID-19 vaccines.

"We ... need every WTO member to step up as well and support an intellectual property waiver, and every company must act ambitiously and urgently to expand manufacturing now," White House spokesperson Karine Jean-Pierre told reporters.

A year after South Africa and India introduced a proposal to temporarily waive intellectual property rights on COVID-19 vaccines and therapies at the WTO, negotiations have failed to make any progress. read more

More than 100 countries backing the waiver say it will help save lives by allowing developing countries to produce COVID-19 vaccines, but the European Union and several countries, including Switzerland, remain opposed.

Read more: Parts of China toughen COVID curbs to fight new outbreak

US President Joe Biden reversed the previous US position to back the proposal in May, but a breakthrough has so far failed to materialize.

WTO Director-General Ngozi Okonjo-Iweala last week conceded the formal negotiations about a temporary waiver were "stuck," but said she believed informal talks were intensifying.

Okonjo-Iweala told a Washington think tank she believed that WTO members could "find a pragmatic compromise on the IP waiver" that would ensure equitable access to vaccines, while preserving incentives for research and innovation.

An EU official described "intense talks" with South Africa about how to boost the availability of vaccines to developing countries, potentially breaking the deadlock. read more

The WTO wants to reach an agreement on the global response to the pandemic at its ministerial conference in Geneva from November 30 to December 3.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ

E-Publications

Most Read